3 results about "Cancer treatment" patented technology

The Body Cavity Cancer Treatment Apparatus generates the magnetic field for use in a combined “Low Temperature Hyperthermia” and ionizing radiation and/or chemotherapy cancer treatment protocol. Unlike other competing systems, the Body Cavity Cancer Treatment Apparatus does not directly kill or ablate the cancer cells with killing temperatures rather, the Body Cavity Cancer Treatment Apparatus stresses the cancer and cancer stem cells by keeping them at a nominal 42° Celsius for some period of time via the heating of nano-particles that have been infused into the bladder, using the generated magnetic field.

The invention belongs to the technical field of polymer material and the field of biomedical engineering, in particular relates to a preparation method for a biodegradable radioactive particle used for curing cancer. The method comprises the following detailed steps: the basic material of the radioactive particle with the needed shape is prepared by using a macromolecular biodegradable material with excellent biocompatibility according to demands; the obtained basic material of the radioactive particle is put into a 0.1 to 0.4mol/l surface modified liquid for dipping and generating aminolysis and carrying out grafting reaction; purified water is used for washing the grafted basic material for removing dissociative functional groups; the obtained basic material is put into a coupling agent liquid to dip for 1 to 2 hours and then is coupled; the obtained basic material is put into the liquid to dip for 12 to 24 hours and then washed to remove the dissociative functional groups; a radioactive isotope is used for replacing the iodine element in the basic material obtained by step (4); and a decoration film is collocated into a liquid and is coated on the surface of the basic material, thus obtaining the needed product. The degradation product is innoxious and harmless, and can be discharged outside the body by metabolism. The preparation method is simple and low in cost.

A pharmaceutical composition for treating cancer, containing a crRNA and an endonuclease as active ingredients is disclosed. The composition can be customized according to the needs of patients or cell types by specifically treating cancer cells on the basis of specific binding properties of DNA and RNA. The nuclease activity of a CRISPR PLUS system, containing both an endonuclease and an exonuclease can be activated by means of the binding between crRNA and a gene specifically found in cancer cells. Therefore, the cancer treatment effect of the composition is more specific than that of other anti-cancer agents that have been developed up till now.